This study of ventilated patients investigated current clinical practice in 476 episodes of pneumonia (48% community-acquired pneumonia, 24% hospital-acquired pneumonia, 28% ventilator-associated pneumonia) using a prospective survey in 14 intensive care units (ICUs) within Australia and New Zealand. Diagnostic methods and confidence, disease severity, microbiology and antibiotic use were assessed.
mended investigations for pneumonia in ventilated patients suggest that both invasive (bronchoscopy, bronchoalveolar lavage, or protected brush specimens) and noninvasive specimen collection (endotracheal aspirates, blood serology and blood cultures) are appropriate 6, 7 . However, despite such recommendations and prevalence data, there is little information documenting current clinical practice and its influence on the diagnosis and management of pneumonia in ventilated Australian and New Zealand patients. As such, this study aimed at describing the clinical management of pneumonia in ICU patients requiring mechanical ventilation in Australia and New Zealand.
METHODS
Fourteen member ICUs of the Clinical Trials Group of the Australian and New Zealand Intensive Care Society (ANZICS-CTG) took part in a prospective survey. All patients requiring ventilation for an admission diagnosis of pneumonia or mechanical ventilation for more than 48 hours irrespective of admission diagnosis were included. The minimum period of data collection was three months. Both invasively and non-invasively ventilated patients were included. The study aimed at collecting information on one hundred admissions for each intensive care unit. Study commencement was just before winter to maximize the number of patients admitted with CAP. Patient demographics, primary diagnoses, length of stay, the McCabe classification of comorbidities (likely to survive ≥ 5 years, between 1-5 years or <1 year) 8 , SAPS II score 9 , duration of mechanical ventilation and outcome were recorded for all patients.
Each clinical episode of pneumonia was described separately. The definitions of pneumonia used by clinicians for inclusion into the study and those used to define a high specificity for pneumonia are detailed in Table 1 [10] [11] [12] [13] . For patients with a clinical diagnosis of pneumonia made by the treating consultant, data collection included clinical signs, subjective confidence in diagnosis by the attending consultant (high >50% likelihood, medium 20-50% likelihood, low <20% likelihood), pneumonia type (CAP, HAP and VAP), clinically determined illness severity (CDIS), sepsis-related organ failure assessment (SOFA) score for the day of admission to the ICU for CAP and HAP and the day of onset for VAP 14 , other suspected or concurrent infections, investigations, microbiology and antibiotic use. Early onset VAP was defined as the onset of a new pneumonic illness in ventilated patients more than 48 hours but less than five days after the commencement of mechanical ventila-tion 15 . Late onset VAP was a new pneumonic illness five for more days from the onset of mechanical ventilation. Inappropriate antibiotic therapy during the first 24 hours in the ICU was defined when the causative organisms were not sensitive on routine laboratory testing to at least one of the antibiotics prescribed. The hospitals taking part in the study received ethical approval from their institutions.
Factors associated with infection risk, mortality predictors and those affecting physician diagnostic confidence and illness severity grading are presented in allied reports 16, 17 .
Sample Size and Statistical Methods
Sample estimation for the survey was determined based on the assumption that bronchoscopy was commonly used in the diagnosis of pneumonia in ventilated patients 6 . The incidence of pneumonia (either CAP or nosocomial) in the ICU was estimated to be 25%. To predict a 30% bronchoscopy use with 95% confidence, 322 pneumonia patients were required 18 . Data were analysed using STATA 7 statistical package TABLE 1 Definitions for pneumonia Community Acquired Pneumonia (CAP) 10 An infection with an onset before or within 48 hours from hospital admission and thought to be pneumonia by the treating clinician.
Hospital Acquired Pneumonia (HAP) 11 A hospital acquired infection is defined as any post operative infection; an infection arising after 48 hours in hospital or an infection arising with 48 hours after discharge from a previous hospital stay in non ventilated patients.
Ventilator Associated Pneumonia (VAP) (after 12 ) ICU acquired infection is defined as an infection arising in ventilated patients 48 hours following admission to the intensive care unit or within 48 hours of ceasing mechanical ventilation with no evidence of pneumonia at the time of commencing mechanical ventilation or the diagnosis of a new infection if the initial presentation was for pneumonia. 
RESULTS
Of the fourteen ICUs in the study, eight were in tertiary referral hospitals with 10 or more ICU beds and the remainder regional units. One thousand, one hundred and twenty-one patients were enrolled with tertiary referral hospitals contributing 64% of all patients. Recruitment was between May 1999 and January 2000, with all participating hospitals enrolling patients for the first three months.
Casemix differences existed between individual hospitals (medical 42-84%, surgical 12-50% and trauma 0-40%, P<0.001) and between hospitals designated as tertiary or regional (medical 48% compared with 64%, P=0.001; surgical 29% compared to 25%, P=0.34 and trauma 23% compared with 10%, P=0.02). Although there were individual hospital variations in the prevalence of scheduled surgical admissions (0-54%, P<0.001), no significant differences between regional and tertiary hospitals were seen (7% compared with 8%, P=0.72).
Clinical Demographics
One hundred and twenty-five (11.2%) of all enrolled patients received non-invasive ventilation (NIV). Three received long-term mechanical ventilation in the community. Only one of these patients had pneumonia. There were 476 episodes of pneumonia including 230 CAPs (48%), 115 HAPs (24%) and 131 VAPs (28%). Eighteen per cent of pneumonia patients received non-invasive ventilation (NIV). Table 2 details the demographic and clinical data for all admissions.
There were significant differences in the prevalence of each pneumonia type in the participating hospitals (CAP 8-62%, HAP 3-23%, VAP 4-21%, P<0.001). The prevalence of CAP and VAP was higher in regional hospitals (CAP 29% compared to 15%, P=0.02, HAP 10% compared with 10%, P=1.00 and VAP 15% compared with 9%, P<0.001). Table 3 details the clinical criteria used for the diagnosis of pneumonia. Patients with clinical signs of consolidation (bronchial breathing or crackles on auscultation) were no more likely to be admitted to the ward before ICU admission (P=0.92).
Severe cardiovascular dysfunction and severe respiratory failure were more common in CAP and HAP while severe CNS dysfunction was more common in VAP (Table 3) . Only 17% of patients with pneumonia met highly specific diagnostic criteria (16% CAP, 20% HAP, 15% VAP, P=0.54). Eighty-three per cent of suspected pneumonia patients had at least two findings of fever, leucocytosis, purulent or changing sputum. Eighty-two per cent had a new or changing chest X-ray infiltrates, 74% had four of the six general criteria used in the Clinical Pulmonary Infection Score 13 and 32% did not isolate a potentially or definitely pathogenic organism. Of suspected pneumonia episodes, 88% per cent were regarded as medium to high diagnostic probability by the attending consultant.
When non-invasive ventilation was used, its mean duration was 2.8 days (range 1-17 days). NIV was most commonly used in CAP (CAP 25%, HAP 15%, VAP 7%; CAP compared to HAP, P=0.02; CAP compared to VAP, P<0.001; HAP compared to VAP, P=0.04). All patients with VAP (N=9) who received NIV also were invasively ventilated. Forty-two per cent of CAP patients and 59% of HAP patients who received non-invasive ventilation also required invasive mechanical ventilation. Although patients with CAP and HAP requiring both non-invasive ventilation and invasive ventilation did not have a difference in total SOFA scores, they did have higher median respiratory SOFA scores (SOFA RESP ), (noninvasive ventilation only SOFA RESP =2 (Range 0-4), non-invasive ventilation and invasive ventilation SOFA RESP = 3 (Range 0-4), P=0.03) and cardiovascular SOFA scores (SOFA CVS ), (non-invasive ventilation only SOFA CVS =0 (Range 0-4), non-invasive ventilation and invasive ventilation SOFA CVS = 1 (Range 0-4), P=0.02). Table 4 describes the diagnostic specimens collected. In patients without respiratory secretion specimens, the median length of ICU stay was shorter (1 day compared to 7 days, P<0.001), purulent tracheal secretions less likely (85 compared to 60%, P=0.02) and non-invasive ventilation more commonly used (40% compared to 15%, P<0.01). These patients had similar outcomes, illness severity, diagnostic confidence and suspected other infections to patients where respiratory secretions were available.
Investigations Performed in the Diagnosis of Pneumonia
Bronchoscopy was used in 26% and not routinely used when other respiratory specimens were not available ( collected for CAP, the only diagnostic specimen was serology in 11% of the serological specimens and pleural fluid culture in 7% of the pleural specimens collected. There were no differences between tertiary and regional hospitals for the performance of serology but tertiary hospitals were less likely to perform blood cultures (OR 0.45, CI 95% 0.32-0.66, P<0.001). Due to the low numbers, individual hospital differences could not be evaluated. Table 6 describes the microorganisms classified as definite pathogens. Fifty-four per cent of suspected pneumonia patients had no definitive isolates. The most common isolates were Streptococcus pneumoniae for CAP (14%) and aerobic gram-negative bacilli for both HAP (22%) and VAP (34%). Twenty per cent of the Streptococcus pneumoniae isolates were of intermediate sensitivity or resistant to penicillin. Twenty per cent of enteric gram-negative isolates were resistant to gentamicin and 31% were resistant to third generation cephalosporins. This finding was similar for all pneumonia types. Polymicrobial infection was present in 6% of CAPs, 7% of HAPs and 14% of VAPs (P=0.02). Early onset VAP (<5 days) showed a greater proportion of Streptococcus pneumoniae and Haemophilus influenzae with late onset VAP (≤ 5 days) more commonly isolating MRSA, Pseudomonas aeruginosa and other enteric gram-negative organisms (P<0.01). The use of antibiotics before the onset of VAP was associated with an increased isolation of high-risk organisms (MRSA, Pseudomonas aeruginosa, Acinetobacter spp and Stenotrophomonas spp -33% compared to 51%, P=0.03).
The Microbiology of Pneumonia Patients

Antibiotic Prescription
The details of antibiotic prescription are summarized in Table 7 . For all pneumonia types, inappropriate antibiotics were prescribed in the first 24 hours in the ICU in 13% of patients. Regional and tertiary referral hospitals had similar rates of inappropriate antibiotic prescription with no differences between individual hospitals.
Patients admitted to the ward prior to ICU for CAP were less likely to have a third generation cephalosporin-macrolide combination than those directly admitted to the ICU (17% compared to 29%, P=0.05). There were no individual hospital differences in the usage of either penicillin or third generation cephalosporins for proven S. pneumoniae pneumonia. There were no differences between individual hospitals in their rate of usage of inappropriate antibiotics for S. pneumoniae, S. aureus, MRSA, or Pseudomonas aeruginosa pneumonia.
For CAP, the use of a third generation cephalosporin-macrolide combination in ICU was predicted by prior therapy with this combination (OR 11.06, CI 95% 3.47-35.3, P<0.001), older patients (OR 1.03, CI 95% 1.01-1.05, P<0.01) and appropriate use of antibiotics (OR 5.54, CI 95% 2.81-10.92, P<0.001) but was protective against mortality (OR 0.37, CI 95% 0.17-0.79, P=0.01) and suspicion of other infections (OR 0.33, CI 95% 0.17-0.79, P=0.04. Hosmer-Lemeshow chi-square=3.24, P=0.98). The cephalosporin-macrolide combination for CAP was not predicted by quartiles of SOFA score, total comorbidities, diagnostic confidence or the presence of clinical signs of consolidation. For CAP, the use of penicillin, amoxicillin or ampicillin was not predicted by ward admission prior to ICU, quartiles of SOFA score, total number of comorbidities, diagnostic confidence or any particular hospital. No patient receiving any simple penicillin before ICU admission had these Aminoglycoside use for CAP was not predicted by the presence of other presumed infections, hospital type, immunosuppression, total comorbidities or mortality. The use of third generation cephalosporins, aminoglycosides and vancomycin for HAP was not predicted by the type of admission, quartiles of SOFA score, diagnostic confidence, hospital type, individual hospital, the suspicion of other infections or patient age. The total number of comorbidities did influence vancomycin prescription (OR 1.45, CI 95% 1.03-2.05, P=0.03).
One tertiary hospital (hospital 3; OR 0.06, CI 95% 0.01-0.54, P=0.01) and two regional hospitals (hospital 2; OR 0.08, CI 95% 0.01-0.77, P=0.03: hospital 8; OR 0.12, CI 95% 0.02-0.87, P=0.04) were less likely to prescribe third generation cephalosporins for VAP. There was no influence on the prescription of third generation cephalosporins by the type of admission, quartiles of SOFA score, the total number of comorbidities nor diagnostic confidence. The only predictor of aminoglycoside use for VAP was prior antibiotic therapy (OR 5.25 CI 95% 3.1-9.0, P<0.001). Vancomycin use in VAP had no specific predictors. Third generation cephalosporin use was less frequent for mild infections (OR 0.38, CI 95% 0.16-0.90, P=0.03), HAP (OR 0.40, CI 95% 0.23-0.72, P<0.01), VAP (OR 0.04, CI 95% 0.02-0.13, P<0.001), suspected aspiration (OR 0.20, CI 95% 0.04-0.92, P=0.04), in one regional (OR 0.26, CI 95% Of the antibiotics changed by day 3, 13% were for inappropriate prescription and 87% were for simplification or other reasons. Changes in antibiotics within the first 3 days of ICU admission was predicted by quartiles of SOFA score (5-6: OR 0.97, CI 95% 0.54- P=0.64) . Although antibiotic changes were more common in VAP, pneumonia type was not an independent predictor. Changes in antibiotics were not predicted by SAPSII score, the total number of comorbidites or any specific comorbidites. There was no antibiotic class preferentially used in relation to clinical signs of consolidation. No individual antibiotic used on the first day in ICU predicted a change in antibiotics within the first three days in ICU.
Patient Outcomes
The median ICU length of stay was similar for CAP and HAP patients but significantly longer for patients with VAP (Table 2 ). Median hospital length of stay was shortest for CAP and longest for VAP ( Table 2 ). The median ICU length of stay was shorter in CAP and HAP patients requiring only NIV (NIV only=3 days (range 1-31), NIV and invasive ventilation=9 days (range 2-38), invasive ventilation only=6.5 Days (range 0.5-85 days), P<0.001). The ICU length of stay was similar for all CAP and HAP patients requiring invasive ventilation when early deaths were excluded (NIV and invasive ventilation=9 days (range 2-38), invasive ventilation alone=7 days (range 2-85) P=0.69). For CAP, admission to the ward before ICU did not influence ICU length of stay, hospital length of stay nor did the use of any antibiotic group before ICU admission.
Although intensive care median length of stay was not associated with CDIS ("mild"=10 days, "severe"=8.5 days, "life-threatening"=9 days. P=0. 29) , it was associated with quartiles of the SOFA score at pneumonia onset (<5=3 days, 5-7= 6 days, 8-10=9 days, >10=12 days. P=<0.001). The highest quartiles of the SAPS II score has a significantly shorter length of stay due to early deaths (<28=9.5 days, 28-38=9 days, 39-49=9days, >49=7 days, P<0.001). By excluding patients with pneumonia who died in the first day of ICU admission, median lengths of ICU stay were similar for all illness severity groups (CDIS -"mild"=10 days, "severe"=9 days, "life-threatening"=9.5 days, P=0.58; quartiles of the SOFA score (<5=10 days, 5-7=9 days, 8-10=9 days, >10=10 days, P=0.84) and quartiles of the SAPS II score (<28=10 days, 28-38=9 days, 39-49=9 days, >49=9 days, P=0.92).
Overall mortality rate did not differ between patients with and without pneumonia. No individual hospital was associated with greater ICU mortality. Community-acquired pneumonia patients died most commonly as a direct result of pneumonia. Pneumonia was never thought to be the direct cause of death in ventilator-associated pneumonia patients ( Table 2) .
DISCUSSION
Patient care improvements require planned research priorities based upon an understanding of current practice as well as investigational protocols. Comparisons and contrasts between CAP, HAP and VAP are limited. This study and its companion studies describe the clinical practice, disease risk 16 , outcome predictors 16 and factors affecting clinical decision making 17 for pneumonia managed in Australian and New Zealand ICUs.
We found CAP prevalence higher than previous reports of 10% 3 , perhaps the effect of our study being conducted principally in the winter months. The proportion of HAPs was lower than the 36% previously reported 20 , probably reflecting definitional differences. VAP prevalence of 12% was at the lower end of published reports which range between 6% and 52% 15, 21 . Importantly, our study confirms that the number of patients meeting highly specific criteria for pneumonia diagnosis is small, reflecting the difficulties of clinical diagnosis 22 .
Bronchoscopy was performed in 26% of the patients but in only 37% of these procedures was a bronchoalveolar lavage performed. This is similar to ward-managed patients 23 . There were no records of protected brush specimen use. Bronchoscopy recommendations for VAP have not been uniformly accepted 7 with its optimal use in CAP and HAP less clear. In an environment where inappropriate antibiotic prescription rates were low, bronchoscopy was not used in the most severely ill and did not improve the isolation of definite isolates and was not associated with improved patient outcome 24 .
Blood culture collection was infrequent but within reported rates (20 to 79%) 3, 25 . Bacteraemia was less common that that reported for both CAP (37%) 26 and nosocomial pneumonia (30%) 27 . The utility of blood cultures is disputed. While positive blood cultures have not been shown to influence physician antibiotic prescription in CAP, significantly change management or outcome 26 , their collection early after presentation may be associated with lower mortality 28 . Serology was infrequently performed but within the reported rates for adults (13 to 85%) 29, 30 . Pleural fluid sampling was higher than published reports but with similar isolation rates for Streptococcus pneumoniae 31 . Fifty-six per cent of patients had no definitive causative microorganism identified reflecting a predominantly clinical approach to pneumonia diagnosis and the low performance of isolation methods in addition to endotracheal aspirates. Isolation rates for causative organisms vary from 30 to 70% for CAP 3, 32 , may be as high as 60% for HAP 2 . Despite using invasive techniques, suspected VAP isolation rates are only 50% 33 . Many VAP cases are excluded solely when isolation of a pathogen is below critical concentration. Despite the relatively low isolation rates from blood cultures, serology and pleural fluid cultures, they are simple and inexpensive to perform with low morbidity and on occasion are the only source of definitive isolates.
The relative incidence of organisms causing CAP was similar to reports for hospitalized patients 34 . The rate of Streptococcus pneumoniae with penicillin resistance of an intermediate or high level in our study was similar to the general Australian experience of 25% 35 . This frequency may well have influenced the use of vancomycin in some patients with CAP. However, the impact of penicillin resistance on clinical practice is debated 36 . The low rates of serology specimen collection may have influenced the isolation rates for atypical organisms 37 . Enteric gram-negative organisms causing severe CAP were isolated with similar prevalence to other studies 37 .
For HAP and VAP in our study, the causative organisms isolated and aminoglycoside resistance were similar to previous reports 11, 38 but the prevalence of polymicrobial infection for VAP of 12% was lower than the 48% reported 39 . This may represent the effect of non-invasive diagnosis or the selection bias of organisms considered by the clinicians to be definite pathogens. Although we found similar temporal patterns of isolation for Pseudomonas aeruginosa and other "high-risk" organisms in VAP, we could not identify a clear separation at 4 to 5 days making their isolation more likely 15 .
Variations in prescribing patterns between different sites have been noted 40 . While recommendations for CAP initial treatment can be drawn from regional guidelines, those for HAP and VAP need to be specific for the institution 41, 42 . For severe CAP during the period of our study, the Australian guidelines recommended using a third generation cephalosporin or a beta-lactam with a beta-lactamase inhibitor and a macrolide 43 . Compliance in our study with national guidelines for CAP was 65% with reported compliance between 50% and 88% 44, 45 . Although there was an increase in the prescribing rates of third generation cephalosporins and macrolides on admission to the ICU, it was not possible to know if the availability of microbiology results influenced change. Aminoglycoside use was similar to that described in the PORT study for CAP patients despite no specific guideline recommendations 34 . Our penicillin and vancomycin use was similar to the 10% and 7% respectively reported in the PORT study 34 as was the median number of antibiotics used per treatment episode.
The delayed or inappropriate prescription of antibiotics for pneumonia is associated with an increased mortality 2 . This finding seems dependent upon high rates of inappropriate antibiotic prescription between 42 and 71% for the sample sizes published. In studies where the inappropriate antibiotic prescription rate was similar to ours (11 to 13%) there was insufficient power to detect a mortality effect 46 .
Consistent with previous studies, the development of VAP significantly prolonged both ICU and hospital lengths of stay 47 . CAP and VAP patients in our study had lengths of ICU and hospital stay comparable to previous descriptions 1, 3, 47, 48 . The mortality of our CAP patients was 33% with that reported between 20 and 54% 3, 49 . HAP requires transfer to the ICU for mechanical ventilation in 10 to 22% of patients 50, 51 . The observed mortality for HAP in our study (37%) was within that reported of 19% to 77% 51, 52 . Our mortality for HAP was similar to previous reports 51 . The influence of VAP on ICU mortality is debated 47, 54 reflecting different methodologies of matching, intensive care case-mix, diagnostic methods, inclusion screening methods, prospective and retrospective designs. Our mortality from VAP (24%) was low compared to reported ranges between 37 and 54% 47, 53 . Despite our study enrolling patients with a clinical diagnosis of pneumonia, many studies requiring quantitative cultures of definitive organisms have similar mortality 33 .
Despite the lack of convincing evidence of efficacy, the use of non-invasive ventilation as part of acute pneumonia management is common 55 . Severe illness of the cardiovascular and respiratory systems predicted the need for invasive ventilation.
Practice variation may be due to casemix differences but has greatest potential to occur when appropriate clinical policies for a given disease are uncer-tain 56 . Importantly, as seen in our study, variations in clinical practice do not always contribute to national health status or mortality rates 57 . Physicians tend to base antibiotic prescribing on the presumed site of infection with little specification of the causative organisms 58 . Broad-spectrum antibiotics are preferred in sick patients to fill gaps in knowledge and are based upon heuristics of the clinical situation 59 . The heuristics in the Australian and New Zealand community appear reasonably calibrated as the inappropriate antibiotic prescription rate is low however, the antibiotics used for pneumonia are broad-spectrum as error margins are small.
Study Strengths and Limitations
This is the only multicentre study in Australia and New Zealand that has prospectively and concurrently examined all pneumonia types treated with mechanical ventilation. Generalization of the findings to a broad intensive care patient population is supported by the range of intensive care units included in the study. Not all units contributed equally to the study sample due to lower admission rates. There were significant casemix differences between the units with several units needing to transfer more seriously ill patients. Although the number of patients enrolled for each pneumonia category was too small for a detailed analysis, important insights into clinical practice were able to be made.
The principal limitation was the reliance on a clinical diagnosis of pneumonia in the absence of a specific diagnostic test. This may have allowed inclusion of patients without pneumonia. This reflects the clinical reality of pneumonia diagnosis. All included patients met the criteria of published definitions [10] [11] [12] . Patients had a high likelihood of having pneumonia as 83% had two or more diagnostic criteria of Fabragas 60 , 74% had 4 of the 6 general criteria of the Clinical Pulmonary Infection Score 13 . Only 12% were assigned a low diagnostic probability and 80% were not considered to have other infections. High specificities have been associated with marked trade-offs in sensitivity. There was insufficient power to find extensive associations using only patients likely to have a highly specific diagnosis. Despite this, the regression models were robust and several previously unreported associations have been described.
SUMMARY AND CONCLUSIONS
Diagnostic practice in Australia and New Zealand ICUs selectively uses invasive methods, largely influenced by individual unit practice. Bronchoscopy does not increase rates of definitive organism isola-tion or influence outcome. There is opportunity to increase the use of blood cultures and serology to improve the identification of causative organisms. Despite this, the prevalence of inappropriate antibiotic prescription is low with practice variation having no impact on mortality. In general clinical ICU practice, a limited diagnostic work up for pneumonia results in an acceptable description of aetiology without adversely affecting patient outcome.
